http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 발행기관 : Shaheed Beheshti University of Medical Sciences (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Song, Ming-Xia,Deng, Xian-Qing,Wei, Zhi-Yu,Zheng, Chang-Ji,Wu, Yan,An, Chang-Shan,Piao, Hu-Ri Shaheed Beheshti University of Medical Sciences 2015 Iranian journal of pharmaceutical research Vol.14 No.1
<P>The microbial resistance has become a global hazard with the irrational use of antibiotics. Infection of drug-resistant bacteria seriously threatens human health. Currently, there is an urgent need for the development of novel antimicrobial agents with new mechanisms and lower levels of toxicity. In this paper, a series of (<I>S</I><I>,Z</I>)-4-methyl-2-(4-oxo-5-((5-substitutedphenylfuran-2-yl) methylene)-2-thioxothiazolidin-3-yl)pentanoic acids via a Knoevenagel condensation were synthesized and evaluated for their antibacterial activity <I>in</I><I>-</I><I>vitro</I>. The synthesized compounds were characterized by IR, <SUP>1</SUP>H NMR and MS. The antibacterial test<I> in</I><I>-</I><I>vitro</I> showed that all of the synthesized compounds had good antibacterial activity against several Gram-positive bacteria (including multidrug-resistant clinical isolates) with minimum inhibitory concentration (MIC) values in the range of 2–4 µg/mL. Especially compounds 4c, 4d, 4e and 4f were the most potent, with MIC values of 2 µg/mL against four multidrug-resistant Gram-positive bacterial strains.</P>
-
Jung, Sang-hoon,Chae, Jung-woo,Song, Byung-jeong,Kwona, Kwang-il Shaheed Beheshti University of Medical Sciences 2014 Iranian journal of pharmaceutical research Vol.13 No.2
<P>Glimepiride/metformin (2/500 mg) is an oral antihyperglycemic agent for the treatment of type 2 diabetes. A generic glimepiride/metformin (2/500 mg) fixed-dose combination (FDC) tablet was developed recently. This study was designed to collect data for submission to Korean regulatory authorities to allow the marketing of the test formulation. We evaluated the comparative bioavailability and tolerability of the test and reference formulations in healthy male adult volunteers. This single-dose, randomized, double-blind, two-way crossover trial was conducted at Bestian Medical Center in Bucheon, Korea. In total, 40 male Korean volunteers were enrolled. The subjects were randomized to receive an FDC tablet containing the glimepiride/metformin (2/500 mg) test or reference formulation, and pharmacokinetic(PK) parameters were measured. After a 1-week washout period, the other formulation was administered and the PK parameters were measured again. The C<SUB>max </SUB>and AUC<SUB>t </SUB>were determined from blood samples obtained at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 h after drug administration. Bioequivalence was considered established if the 90% CIs of the geometric mean ratios(GMRs) of the test-to-reference formulations for C<SUB>max </SUB>and AUC<SUB>t </SUB>were within the predetermined regulatory range of 80-125%. In total, 40 healthy male subjects were enrolled and completed the study (mean [SD] age, 23.2[2.26]years[range, 19-30years];weight, 68.95[8.30]Kg[range, 52.0-87.0 Kg]; and height, 175.4[5.34] cm[range, 164-189 cm]). The GMRs(90% CI) of the glimepiride C<SUB>max </SUB>and AUC<SUB>t </SUB>were 1.006(0.947-1.069) and 1.010(0.953-1.071), respectively. For metformin, the values were 1.019(0.959-1.083) and 1.035(0.989-1.084), respectively. The test and reference formulations had similar PK parameters. The test formulation of glimepiride/metformin (2/500 mg) FDC tablets met the Korean regulatory criteria for bioequivalence. </P>
-
Kwon, Jung-Taek,Jiang, Hu-Lin,Minai-Tehrani, Arash,Gyu Woo, Chang,Choi, Mansoo,Cho, Chong-Su,Kim, Yeon-Soo,Cho, Myung-Haing Shaheed Beheshti University of Medical Sciences 2013 Iranian journal of pharmaceutical research Vol.12 No.2
<P>Chitosan-<I>graft</I>-polyethylenimine (CHI-<I>g</I>-PEI) copolymer has been used for the improvement of low transfection efficiency of chitosan. The present study aims to test the pulmonary toxicity and efficiency of CHI-<I>g</I>-PEI as an aerosol gene carrier. Mice were exposed to aerosol containing green-fluorescent protein (GFP)-polyethylenimine (PEI) or GFP-CHI-<I>g</I>-PEI complexes for 30 min during the development of our nose-only exposure chamber (NOEC) system. CHI-<I>g</I>-PEI-mediated aerosol delivery demonstrated 15.65% enhancement of the fluorescence intensity. Compared to PEI, CHI-<I>g</I>-PEI showed no significant pulmonary toxicity. In summary, using CHI-<I>g</I>-PEI is safe and shows high transfection in aerosol gene delivery to animals, and enhanced efficiency was achieved through our aerosol gene delivery system. Therefore, CHI-<I>g</I>-PEI and this system would be applicable to future study for aerosol gene therapy. </P>
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
